Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 1 , Pages 57-69 , February 2010

GI-lymphomas in immunosuppressed patients (organ transplantation; HIV)

This review will be dedicated to Prof. Ernst-Otto Riecken.

  • Walter Heise, MD, PhD (Head of Department, Gastroenterology)

      Affiliations

    • Ev. Hospital Königin Elisabeth Herzberge, Dept. Internal Medicine, Herzbergstr. 79, 10365 Berlin, Germany
    • Academic Teaching Hospital Humboldt University, Berlin, Germany
    • Corresponding Author InformationTel.: +49 30 5472 3701; fax: +49 30 5472 3703.

References 

  1. Oertel SH, Riess H. Immunosurveillance, immunodeficiency and lymphoproliferations. Recent Results Cancer Res. 2002;159:1–8
  2. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol. 1999;12(2):200–217
  3. Penn J. The occurence of malignant tumors in immuno-suppressed states. Prog Allergy. 1986;37:259–300
  4. Khodadad A, Aghamohammadi A, Parveneh N, Rezaei N, Mahjoob F, Bashashati M, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci. 2007;52:2977–2983
  5. Washington K, Stenzel TT, Burckley RH, Gottfried MR. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol. 1996;20(10):1240–1252
  6. Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID). Am J Surg Pathol. 2007;31(12):1800–1812
  7. Oksenhendler E, Gérard L, Fieschi C, Malphettes M, Mouillot G, Jaussaud R, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008;46:1547–1554
  8. Cunningham-Rundles C, Siegal FP, Cunningham-Rundles S, Lieberman P. Incidence of cancer in 98 patients with common varied immunodeficiency. J Clin Immunol. 1987;7:294–299
  9. Hermans PE, Diaz-Buxo JA, Stobo JD. Idiopathic late-onset immunoglobulin deficiency. Clinical observations in 50 patients. Am J Med. 1976;61:221–237
  10. Atarod L, Raissi A, Aghamohammadi A, Farhoudi A, Khodadad A, Moin M, et al. A review of gastrointestinal disorders in patients with primary antibody immunodeficiencies during a 10-year period (1990–2000), in Children Hospital Medical Center. Iran J Allergy Asthma Immunol. 2003;2(2):75–79
  11. Lai Ping So A, Mayer L. Gastrointestinal manifestations of primary immunodeficiency disorders. Semin Gastrointest Dis. 1997;8(1):22–32
  12. Ridolfo AL, Santambrogio S, Mainini F, Vago L, Gervasoni C, Gori A, et al. High frequency of non-Hodgkin's lymphoma in patients with HIV-associated Kaposi’s sarcoma. AIDS. 1996;10:181–185
  13. Heise W, Arastéh K, Mostertz P, Skörde J, Schmidt W, Obst C, et al. Malignant gastrointestinal lymphoma in patients with AIDS. Digestion. 1997;58:218–224
  14. Bonnet F, Chene G. Evolving epidemiology of malignancies in HIV. Curr Opin Oncol. 2008;20(5):534–540
  15. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology. 2002;16(4):441–459
  16. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly activeantiretroviral therapy. Oncologist. 2005;10:412–426
  17. Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008;22(4):489–496
  18. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;21(18):3447–3453
  19. Silverberg MJ, Abrams DI. Do antiretrovirals reduce the risk of non-AIDS-defining malignancies?. Curr Opin HIV AIDS. 2009;4(1):42–51
  20. Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H. High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review. Dtsch Med Wochenschr. 2006;131:1849–1852
  21. Beck PL, Gill MJ, Sutherland LR. HIV-associated non-Hodgkin's lymphoma of the gastrointestinal tract. Am J Gastroenterol. 1996;91:2377–2381
  22. Imrie KR, Sawka CA, Kutas G, Brandwein J, Warner E, Burkes R, et al. HIV-associated lymphoma of the gastrointestinal tract: the University of Toronto AIDS-lymphoma study group experience. Leuk Lymphoma. 1995;16(3–4):343–349
  23. Carbone A. AIDS-related Non-Hodgkin's lymphomas: from pathology and molecular pathogenesis to treatment. Hum Pathol. 2002;33:392–404
  24. Herndier BG, Friedman SL. Neoplasms of the gastrointestinal tract and hepatobiliary system in acquired immunodeficiency syndrome. Semin Liver Dis. 1992;12(2):128–141
  25. Ho-Yen C, Chang F, van der Walt J, Lucas S. Gastrointestinal malignancies in HIV-infected or immunosuppressed patients. Adv Anat Pathol. 2007;14(6):431–443
  26. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83:804–809
  27. Carbone A, Gloghini A. AIDS-related lymphomas: from pathogenesis to pathology. Br J Haematol. 2005;130:662–670
  28. Bellan C, De Falco G, Lazzi S, Leoncini L. Pathologic aspects of AIDS malignancies. Oncogene. 2003;22:6639–6645
  29. Whooley BP, Bernik S, Sarkis AY, Wallack MK. Primary gastrointestinal non-Hodgkin's lymphoma: increasingly AIDS-related. Am Surg. 1998;64:137–143
  30. Parente F, Rizzardini G, Cernuschi M, Antinori S, Fasan M, Bianchi Porro G. Non-Hodgkin's lymphoma and AIDS: frequency of gastrointestinal involvement in al large Italian series. Scand J Gastroenterol. 1993;28:315–318
  31. Powitz F, Bogner JR, Sandor P, Zietz C, Goebel FD, Zoller WG. Gastrointestinal lymphomas in patients with AIDS. Z Gastroenterol. 1997;35:179–185
  32. Hernández JA, Navarro JT, Ribera JM, Sancho JM, Vaquero M, Sirera G, et al. Primary gastrointestinal lymphomas in patients infected with HIV: study of 15 cases in a series of 76 patients with non-Hodgkin's lymphoma and HIV infection. Med Clin (Barc). 1999;112(6):222–224
  33. Cappell MS, Botros N. Predominantly gastrointestinal symptoms and signs in 11 consecutive AIDS patients with gastrointestinal lymphoma: a multicenter, multiyear study including 763 HIV-sero's positive patients. Am J Gastroenterol. 1994;89(4):545–554
  34. Girard T, Luquet-Besson I, Baran-Marszak F, Raphaël M, Boué F. HIV + MALT lymphoma remission induced by highly active antiretroviral therapy alone. Eur J Haematol. 2005;74(1):70–72
  35. Carbone A. Emerging pathways in the development of AIDS-related lymphomas. Lancet Oncol. 2003;4:22–29
  36. Lichterfeld M, Lorenz C, Nischalke HD, Scheurlen C, Sauerbruch T, Rockstroh JK. Decreased prevalence of Helicobacter pylori infection in HIV patients with AIDS defining diseases. Z Gastroenterol. 2002;40(1):11–14
  37. Chiu HM, Wu MS, Hung CC, Shun CT, Lin JT. Low prevalence of Helicobacter pylori but high prevalence of Cytomegalovirus-associated peptic ulcer disease in AIDS patients: comparative study of symptomatic subjects evaluated by endoscopy and CD4 cell count. J Gastroenterol Hepatol. 2004;19(4):423–438
  38. Pedersen C, Barton SE, Chiesi A, Skinhøj P, Katlama C, Johnson A, et al. HIV-related non-Hodgkin's lymphoma among European AIDS patients. Eur J Haematol. 1995;55(4):245–250
  39. Schürmann D, Grünewald T, Weiss R, Jautzke G, Pohle HD, Ruf B. Intensive treatment of AIDS-related non-Hodgkin's lymphoma with the MACOP-B protocol. Eur J Haematol. 1995;54(2):73–77
  40. Fasan ML, Morandi E, Fociani P, Benatti SV, Mainini A, Ridolfo AL, et al. AIDS-associated gastrointestinal lymphoma. Is there a role for surgery in the standard of care?. J Acquir Immune Defic Syndr. 2003;34(3):345–355
  41. Weiss R, Mitrou P, Arasteh K, Schuermann D, Hentrich M, Duehrsen U, et al. Acquired immunodeficiency syndrome-related lymphoma. Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-Results of the German multicenter trial. Cancer. 2006;106(7):1560–1568
  42. Diamond C, Taylor TH, Aboumrad T, et Anton-Culver H. Changes in Immunodeficiency syndrome-related non-Hodgkin's lymphoma in the era highly active antiretroviral therapy. Cancer. 2006;106:128–131
  43. Nutankalva L, Wutoh AK, McNeil J, Frederick WR, Reddy RB, Daftary M, et al. Malignancies in HIV: pre- and post-highly active antiretroviral therapy. J Natl Med Assoc. 2008;1000:817–820
  44. Andrews CN, John Gill MJ, Urbanski SJ, Stewart D, Perini R, Beck P. Changing epidemiology and risk factors for gastrointestinal non-Hodgkin's lymphoma in a North American population: population-based study. Am J Gastroenterol. 2008;103:1762–1769
  45. Diamond C, Taylor TH, Im T, Miradi M, Anton-Culver H. Improved survival and chemotherapy response among patients with AIDS-related non-Hodgkin's lymphoma receiving highly active antiretroviral therapy. Hematol Oncol. 2006;24:139–145
  46. Vaccher E, Spina M, Talamini R, Zanetti M, di Gennaro G, Nasti G, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis. 2003;37:1556–1564
  47. Hoffmann C, Wolf F, Fätkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003;17(10):1521–1529
  48. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active antiretroviral therapy on response to treatment and survival in patients with Acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol. 2001;112(4):909–915
  49. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2007;140:411–419
  50. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171–2178
  51. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653–4659
  52. Costello RT, Zerazhi H, Charbonnier A, de Colella JM, Alzieu C, Poizot-Martin I, et al. Intensive sequential chemotherapy with hematopoetic growth factor support for non-Hodgkin lymphoma in patients infected with human immunodeficiency virus. Cancer. 2004;100:667–676
  53. Kaplan LD, Lee JY, Ambinder RF, Ambinder RF, Sparano JA, Cesarman E, et al Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-malignancies consortium trial 010. Blood. 2005;106(5):1538–1543
  54. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol. 2006;24:4123–4128
  55. Re A, Cattaneo C, Michieli M, Casari S, Spina M, Rupolo M, et al. High dose therapy and autologous peripheral stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving with highly active antiretroviral therapy. J Clin Oncol. 2003;21:4423–4427
  56. Krishnan A. Stem cell transplantation in HIV-infected patients. Curr Opin HIV AIDS. 2009;4(1):11–15
  57. Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant. 2007;1:4–10
  58. Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery. 1978;83:492
  59. Nash CL, Price LM, Stewart DA, Sepandj F, Yilmaz S, Barama A. Early gastric post-transplantation lymphoproliferative disorder and H. pylori detection after kidney transplantation: a case report and review of the literature. Can J Gastroenterol. 2000;14(8):721–724
  60. Schwend M, Tiemann M, Kreipe HH, Parwaresch MR, Kraatz EG, Herrmann G, et al. Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart transplantation. Eur Respir J. 1994;7:612–616
  61. Weintraub J, Warnke RA. Lymphoma in cardiac allotransplant recipients. Transplantation. 1982;33(4):347–351
  62. Kusuki S, Hashii Y, Fukushima N, Takizawa S, Tokimasa S, Kogaki S, et al. Pediatric post-transplant diffuse large B-cell lymphoma after cardiac transplantation. Int J Hematol. 2009;89(2):209–213
  63. Trappe R, Oertel S, Riess H. Pathogenetic, clinical, diagnostic, and therapeutic aspects of post-transplantation lymphoproliferative disorders. Dtsch Arztebl. 2006;103(48):3258–3267
  64. Sebire NJ, Malone M, Risdon RA, Ramsay AD. Epstein-Barr virus-associated lymphoproliferative disorders presenting as apparently isolated gastrointestinal lesions in childhood. Pediatr Dev Pathol. 2005;8:88–91
  65. Younes BS, Ament ME, McDiarmid SV, Martin MG, Vargas JH. The involvement of the gastrointestinal tract in posttransplant lymphoproliferative disease in pediatric liver transplantation. J Pediatr Gastroenterol Nutr. 1999;28:380–385
  66. Shitrit D, Shitrit AB, Dickman R, Sahar G, Saute M, Kramer MR. Gastrointestinal involvement of posttransplant lymphoproliferative disorder in lung transplant: report of a case. Dis Colon Rectum. 2005;48(11):2144–2147
  67. Ojha J, Islam Cohen DM, Marshal D, Reavis MR, Bhattacharyya I. Post-transplant lymphoproliferative disorders of oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105(5):589–596
  68. Tsai DE, Hardy CL, Tomashzewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorders: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;8:1076–1088
  69. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol; 11(Suppl. 1): 45–48.
  70. Comoli P, Maccario R, Locatelli F, Valente U, Basso S, Garaventa A, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T-cells. Am J Transplant. 2005;6:1415–1422
  71. Choquet S, Leblond , Herbrecht R, Socié G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplant lymphoproliferative disorders: results of a prospective multicentre phase 2 study. Blood. 2006;107:3053–3057
  72. Van Hogezand RA, Eichhorn RF, Choudry A, Veenendaal RA, Lamers CB. Malignancies in inflammatory bowel disease: fact or fiction?. Scand J Gastroenterol Suppl. 2002;(236):48–53
  73. Bernstein D, Rogers A. Malignancy in Crohn's disease. Am J Gastroenterol. 1996;91(3):434–440
  74. Loftus EV, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000;95(9):2308–2312
  75. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001;121:1080–1087
  76. Tan CW, Wilson GE, Howat JM, Shreeve DR. Rectal lymphoma in ulcerative colitis treated with azathrioprine. Eur J Gastroenterol Hepatol. 2001;13(8):989–992
  77. Losco A, Gianelli U, Cassani B, Baldini L, Conte D, Basilisco G. Epstein-Barr virus-associated lymphoma in Crohn's disease. Inflamm Bowel Dis. 2004;10(4):425–429
  78. Bebb JR, Logan PH. Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?. Aliment Pharmacol Ther. 2001;15:1843–1849
  79. Jones JL, Loftus EV. Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?. Inflamm Bowel Dis. 2007;13(10):1299–1307
  80. Drini M, Prichard PJ, Brown BJ, Macrae FA. Hepatoplenic T-cell lymphoma following infliximab therapy for Crohn's disease. Med J Aust. 2008;189(8):464–465
  81. Girard C, Guillot B, Bessis D. Gastric MALT lymphoma in a patient receiving infiliximab for psoriasis. Br J Dermatol. 2008;159(2):497–498
  82. Shepherd NA, Hall PA, Williams GT, Codling BW, Jones EL, Levison DA, et al. Primary malignant lymphoma of the large intestine complicating chronic inflammatory disease. Histopathology. 1989;15(4):325–337
  83. Kwon JH, Farrrell RJ. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol. 2005;56:169–178
  84. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate or anti-tumor necrosis factor therapy in 1857 patients. Arthritis Rheum. 2004;50:1740–1751

PII: S1521-6918(10)00002-8

doi: 10.1016/j.bpg.2010.01.001

Best Practice & Research Clinical Gastroenterology
Volume 24, Issue 1 , Pages 57-69 , February 2010

Article Tools

* Image Usage & Resolution